Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE

J Clin Lipidol. 2016 Nov-Dec;10(6):1397-1405.e2. doi: 10.1016/j.jacl.2016.09.011. Epub 2016 Sep 22.

Abstract

Background: A substantial proportion of individuals clinically diagnosed as familial hypercholesterolemia (FH) do not carry pathogenic mutations in candidate genes. Whether in them the high cholesterol trait is transmitted monogenically has not been studied.

Objectives: We assessed the inheritance pattern, penetrance, and expression of high low-density lipoprotein (LDL)-cholesterol (LDLc) in families with genetic hypercholesterolemia (GH) without known causative mutations (non-FH-GH).

Methods: The study included probands with a clinical diagnosis of FH and their families attending 2 lipid clinics in Spain. Inclusion criteria for probands were LDLc >95th percentile, triglycerides <90th percentile, at least 1 first-degree family member with LDLc >90th percentile, >5 points in the Dutch Lipid Clinic Network criteria score, and absence of mutations in LDLR, APOB, PCSK9 or APOE. Eleven FH families with a LDLR mutation were also examined for comparison.

Results: We analyzed 49 non-FH-GH probands and 277 first-and second-degree relatives. LDLc was >90th percentile in 37.8% of blood relatives, at concentrations similar to those of probands. LDLc had a normal distribution in non-FH-GH families, in contrast with a bimodal distribution in FH families. When a dominant model was tested, family-based association tests gave much lower heritability values for total cholesterol and LDLc in non-FH-GH (0.39 and 0.32, respectively) than in FH (0.78 and 0.61, respectively).

Conclusions: Non-FH-GH families have a milder lipid phenotype than genetically defined FH. The heritage pattern of LDLc in non-FH-GH does not fit with a monogenic disorder. Our findings support the concept that most non-FH-GHs are polygenic hypercholesterolemias.

Keywords: Familial hypercholesterolemia; Family study; Heritability; Hypercholesterolemia; Segregation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Apolipoprotein A-I / blood
  • Apolipoproteins B / blood
  • Apolipoproteins B / genetics*
  • Apolipoproteins E / genetics*
  • Body Mass Index
  • C-Reactive Protein / analysis
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Female
  • Humans
  • Hyperlipoproteinemia Type II / diagnosis*
  • Hyperlipoproteinemia Type II / genetics
  • Lipoprotein(a) / blood
  • Male
  • Middle Aged
  • Phenotype
  • Polymorphism, Single Nucleotide
  • Proprotein Convertase 9 / genetics*
  • Receptors, LDL / genetics*
  • Triglycerides / blood

Substances

  • Apolipoprotein A-I
  • Apolipoproteins B
  • Apolipoproteins E
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Lipoprotein(a)
  • Receptors, LDL
  • Triglycerides
  • C-Reactive Protein
  • PCSK9 protein, human
  • Proprotein Convertase 9